FDA-approved1,2Evidence: Smaller human trialsBrain, nerves and sleep

Trofinetide1

Also called Daybue1,2

Key takeaway

Trofinetide is a small synthetic molecule built from three amino-acid units, and the active ingredient in Daybue.1,2 FDA approved Daybue in 2023 for Rett syndrome in adults and children 2 years and older. The label states that how it works in Rett syndrome is unknown.1,2 In a 12-week randomized, placebo-controlled trial of 187 patients aged 5 to 20, it improved caregiver-rated symptoms and clinician ratings. The label states that most patients had diarrhea.1

Trofinetide at a glance

What it isAccording to the chemical name in its label, trofinetide is built from glycine, a modified proline and glutamic acid. The label states that its mechanism in Rett syndrome is unknown.1
FDA statusFDA-approved. Drugs@FDA lists Daybue with an original approval date of March 10, 2023. The cited label has no boxed warning.1,2
Human evidenceOne 12-week randomized, double-blind, placebo-controlled trial in 187 patients aged 5 to 20 with Rett syndrome, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is trofinetide?

Trofinetide is a synthetic compound whose chemical name in the label describes three linked amino-acid units: glycine, a methylated proline and glutamic acid.1

In the United States it is the active ingredient of Daybue, from Acadia Pharmaceuticals, according to Drugs@FDA.2

How does trofinetide work?

The label states that the mechanism by which trofinetide has its effect in Rett syndrome is unknown.1

What do human studies show?

The label describes a 12-week randomized, double-blind, placebo-controlled trial (Study 1) in 187 patients aged 5 to 20 with Rett syndrome and a disease-causing MECP2 mutation; 93 received trofinetide and 94 placebo.1

Its two main measures were a caregiver-rated Rett syndrome behaviour questionnaire and a clinician’s global rating of improvement. Trofinetide showed a statistically significant difference from placebo on both at week 12, according to the label.1

The label reports that 85% of patients treated with it in Study 1 and longer-term studies had diarrhea.1

What the evidence base contains

  • Controlled human trial Study 1 (NCT04181723): a 12-week randomized, double-blind, placebo-controlled trial in 187 patients aged 5 to 20 with Rett syndrome and a confirmed MECP2 mutation, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is trofinetide FDA-approved?

Yes. Drugs@FDA lists Daybue, application NDA 217026, with an original approval date of March 10, 2023.2

The Daybue label cited here (DailyMed SPL version 12, published September 11, 2026) states that it is indicated for the treatment of Rett syndrome in adults and children 2 years of age and older.1

The label has no boxed warning and lists no contraindications. Its warnings cover diarrhea, weight loss, and vomiting followed by aspiration pneumonia.1

Timeline

  1. FDA approves Daybue, according to Drugs@FDA.2
  2. DailyMed publishes the Daybue label version cited on this page.1

What is still unknown?

How it works: the label states that its mechanism in Rett syndrome is unknown.1

Its effects beyond 12 weeks of controlled comparison, since the trial described in the label lasted 12 weeks.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Trofinetide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Trofinetide are a bounded selection, not every registration or paper about Trofinetide. For the years before Trofinetide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Trofinetide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Trofinetide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Daybue for Rett syndrome. A 12-week randomized, placebo-controlled trial of 187 patients described in the label found improvement on caregiver and clinician ratings. The label states that its mechanism is unknown and that most patients had diarrhea.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Trofinetide?

FDA-approved as Daybue for Rett syndrome. A 12-week randomized, placebo-controlled trial of 187 patients described in the label found improvement on caregiver and clinician ratings. The label states that its mechanism is unknown and that most patients had diarrhea.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
5
Drugs@FDA applications
2

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.↗Source date October 1, 2026
  2. Literature metadata · added November 15, 2026

    Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States.↗Source date September 26, 2026
  3. Literature metadata · added November 15, 2026

    Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States.↗Source date August 28, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Trofinetide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

27Selected dated records
29Connected citations
5Populated source years2020–2026
3/4Record lanes present

Registered human studies

Trial composition

3 of 3 selected trial records include at least one phase value; 3 of 3 include a status value in the retained structured contract.

PhasesPhase 3 2Phase 2 1
Status at observationCompleted 3

PubMed bibliography

Publication composition

20 of 20 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 19Research Support, Non-U.S. Gov't 3Clinical Trial, Phase III 2Comment 1Letter 1Randomized Controlled Trial 1Research Support, N.I.H., Extramural 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
2
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
27

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 27 dated records

Research hub

Explore the Trofinetide evidence record

Open all 27 records →
27Dated records
3Evidence types
27Cited public sources
5Source years

Change ledger

Recently changed for Trofinetide

Open all 27 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT02715115

PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide.

PeptideScanner change date
November 15, 2026
Cited source date
August 14, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04181723

PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide.

PeptideScanner change date
November 15, 2026
Cited source date
April 8, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04279314

PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide.

PeptideScanner change date
November 15, 2026
Cited source date
April 11, 2024
Evidence lane
Clinical trials

Official-source collections

Source records for Trofinetide

Open the full research atlas →
PubMed20

20 with attributed title, venue, publication-date, and type metadata.

  1. Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis.Journal of computational chemistry · 2026 Aug 05
  2. Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States.Frontiers in neurology · 2026 07 27
  3. Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.Advances in therapy · 2026 06 30
Explore all selected literature →
ClinicalTrials.gov3

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT04279314Registry update April 11, 2024 · completed at observation
  2. NCT04181723Registry update April 8, 2024 · completed at observation
  3. NCT02715115Registry update August 14, 2020 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span August 14, 2020 to October 1, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 27

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.↗

    PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States.↗

    PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States.↗

    PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome.↗

    PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis.↗

    PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method.↗

    PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues.↗

    PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy.↗

    PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Rett syndrome and real-world treatment patterns of trofinetide in the United States.↗

    PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Trofinetide treatment for Rett syndrome: Lessons to learn.↗

    PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.↗

    PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Regulatory

    Drugs@FDA application NDA219884↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    DAYBUE (trofinetide) solution; DAYBUE STIX (trofinetide) for solution · SPL version 12 · published 2026-09-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: DAYBUE (trofinetide), NDA 217026 · original approval March 10, 2023 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026